Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 16 | 2012 | 347 | 1.420 |
Why?
|
| Interferon-alpha | 13 | 2011 | 242 | 0.940 |
Why?
|
| Antiviral Agents | 15 | 2011 | 768 | 0.870 |
Why?
|
| Polyethylene Glycols | 12 | 2011 | 243 | 0.810 |
Why?
|
| Liver Cirrhosis | 11 | 2011 | 877 | 0.770 |
Why?
|
| Tracheostomy | 1 | 2022 | 198 | 0.660 |
Why?
|
| Ribavirin | 7 | 2011 | 86 | 0.560 |
Why?
|
| Caregivers | 1 | 2022 | 548 | 0.550 |
Why?
|
| Recombinant Proteins | 12 | 2011 | 1399 | 0.260 |
Why?
|
| Coffee | 2 | 2011 | 26 | 0.260 |
Why?
|
| Disease Progression | 11 | 2012 | 2103 | 0.250 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2011 | 949 | 0.220 |
Why?
|
| Liver Neoplasms | 5 | 2011 | 1334 | 0.200 |
Why?
|
| Ownership | 1 | 2022 | 33 | 0.200 |
Why?
|
| Hepatitis C | 2 | 2010 | 372 | 0.180 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2010 | 45 | 0.160 |
Why?
|
| Genetic Markers | 1 | 2011 | 611 | 0.160 |
Why?
|
| ErbB Receptors | 1 | 2011 | 287 | 0.160 |
Why?
|
| Learning | 1 | 2022 | 364 | 0.160 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 820 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2011 | 2687 | 0.130 |
Why?
|
| Middle Aged | 17 | 2012 | 27028 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2010 | 456 | 0.130 |
Why?
|
| Parents | 1 | 2022 | 1028 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 2194 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 1129 | 0.090 |
Why?
|
| Portal System | 1 | 2011 | 34 | 0.090 |
Why?
|
| Biomarkers | 4 | 2011 | 3153 | 0.090 |
Why?
|
| Male | 17 | 2012 | 62009 | 0.090 |
Why?
|
| Interleukins | 1 | 2011 | 121 | 0.090 |
Why?
|
| Vitamin D | 1 | 2012 | 167 | 0.080 |
Why?
|
| Prospective Studies | 6 | 2011 | 6175 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 1168 | 0.080 |
Why?
|
| Hepatitis B | 1 | 2011 | 163 | 0.080 |
Why?
|
| Female | 17 | 2012 | 67310 | 0.080 |
Why?
|
| Humans | 19 | 2022 | 126285 | 0.080 |
Why?
|
| Hepatocytes | 1 | 2011 | 210 | 0.080 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2009 | 65 | 0.080 |
Why?
|
| Gene Frequency | 2 | 2011 | 734 | 0.080 |
Why?
|
| Iron | 1 | 2011 | 281 | 0.070 |
Why?
|
| Viral Load | 2 | 2011 | 393 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2009 | 191 | 0.070 |
Why?
|
| RNA, Viral | 2 | 2011 | 538 | 0.070 |
Why?
|
| Aspartate Aminotransferases | 2 | 2011 | 85 | 0.070 |
Why?
|
| Alanine Transaminase | 2 | 2011 | 158 | 0.060 |
Why?
|
| Platelet Count | 2 | 2011 | 137 | 0.060 |
Why?
|
| Logistic Models | 2 | 2011 | 1811 | 0.060 |
Why?
|
| Models, Biological | 1 | 2011 | 1470 | 0.060 |
Why?
|
| Time Factors | 4 | 2011 | 6334 | 0.060 |
Why?
|
| United States | 5 | 2011 | 10988 | 0.060 |
Why?
|
| Hepacivirus | 2 | 2011 | 252 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2011 | 5199 | 0.060 |
Why?
|
| Adult | 7 | 2012 | 29791 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2011 | 12379 | 0.050 |
Why?
|
| Child | 1 | 2022 | 24740 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2011 | 114 | 0.050 |
Why?
|
| Bilirubin | 1 | 2011 | 125 | 0.040 |
Why?
|
| Genotype | 2 | 2011 | 2593 | 0.040 |
Why?
|
| Propensity Score | 1 | 2011 | 228 | 0.040 |
Why?
|
| Risk Factors | 3 | 2011 | 10372 | 0.040 |
Why?
|
| Prevalence | 2 | 2011 | 2483 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 588 | 0.040 |
Why?
|
| Incidence | 2 | 2011 | 3166 | 0.040 |
Why?
|
| Liver Transplantation | 2 | 2011 | 1077 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1072 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1436 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2010 | 479 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 1266 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 1378 | 0.030 |
Why?
|
| Prognosis | 2 | 2011 | 4731 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2011 | 1193 | 0.030 |
Why?
|
| Alleles | 1 | 2010 | 1624 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2011 | 4873 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 3459 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 4321 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 131 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 324 | 0.020 |
Why?
|
| Interferons | 1 | 2011 | 128 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 240 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 3203 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 447 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 2009 | 9 | 0.020 |
Why?
|
| Database Management Systems | 1 | 2009 | 31 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 133 | 0.020 |
Why?
|
| Liver Failure | 1 | 2009 | 89 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 274 | 0.020 |
Why?
|
| Cause of Death | 1 | 2011 | 477 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 247 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1341 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 709 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3341 | 0.010 |
Why?
|
| Biopsy | 1 | 2008 | 1257 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 885 | 0.010 |
Why?
|
| Liver | 1 | 2008 | 1758 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 6645 | 0.010 |
Why?
|
| Aged | 1 | 2011 | 19960 | 0.010 |
Why?
|